Blood test and patient surveys aim to outsmart vulva cancer recurrence
NCT ID NCT06495554
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether regular patient surveys and a special blood test (circulating tumor DNA) can spot vulva cancer returning earlier than standard check-ups. About 295 women with vulva cancer will fill out symptom surveys every four months and give blood samples for two years. The goal is to improve how doctors monitor for recurrence and manage side effects, potentially leading to better outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRCULATING TUMOR DNA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aarhus University Hospital
RECRUITINGAarhus N, 8200, Denmark
-
Copenhagen University Hospital
RECRUITINGCopenhagen, 2100, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can a single online class help cancer survivors sleep better?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- Hidden heart risks in testicular cancer survivors: a closer look at chemotherapy's long shadow
- Time-Restricted eating may ease lingering cancer fatigue
- New imaging tool could help surgeons detect hidden cancer cells during surgery